We recently reported that Drosophila Insensitive (Insv) promotes sensory organ development and has activity as a nuclear corepressor for the Notch transcription factor Suppressor of Hairless [Su(H)]. Insv lacks domains of known biochemical function but contains a single BEN domain (i.e., a "BEN-solo" protein). Our chromatin immunoprecipitation (ChIP) sequencing (ChIP-seq) analysis confirmed binding of Insensitive to Su(H) target genes in the Enhancer of split gene complex [E(spl)-C]; however, de novo motif analysis revealed a novel site strongly enriched in Insv peaks (TCYAATHRGAA). We validate binding of endogenous Insv to genomic regions bearing such sites, whose associated genes are enriched for neural functions and are functionally repressed by Insv. Unexpectedly, we found that the Insv BEN domain binds specifically to this sequence motif and that Insv directly regulates transcription via this motif. We determined the crystal structure of the BEN-DNA target complex, revealing homodimeric binding of the BEN domain and extensive nucleotide contacts via α helices and a C-terminal loop. Point mutations in key DNA-contacting residues severely impair DNA binding in vitro and capacity for transcriptional regulation in vivo. We further demonstrate DNA-binding and repression activities by the mammalian neural BEN-solo protein BEND5. Altogether, we define novel DNA-binding activity in a conserved family of transcriptional repressors, opening a molecular window on this extensive gene family.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3613608 | PMC |
http://dx.doi.org/10.1101/gad.213314.113 | DOI Listing |
J Adv Nurs
January 2025
Faculty of Health, Sports and Social Work, Inholland University of Applied Sciences, Amsterdam, The Netherlands.
Aim: The aim of this study was to provide insights into how, through exploring goal-setting interventions, a nursing team in geriatric rehabilitation might refine their patient-centred strategies.
Design: The study design was participatory action research (PAR).
Method: Team members and nursing students, under the guidance of a facilitator, performed two PAR cycles.
J Head Trauma Rehabil
January 2025
Mental Health Service Line, Minneapolis VA Health Care System, Minneapolis, Minnesota (Tsen); Department of Physical Medicine and Rehabilitation, Rehabilitation & Extended Care, Minneapolis VA Health Care System, Minneapolis, Minnesota (Dr Finn); Department of Psychiatry & Behavioral Sciences, University of Minnesota, Minneapolis, Minnesota (Dr Finn); Department of Research Methodology and Biostatistics, Morsani College of Medicine, University of South Florida, Tampa, Florida (Mrs Klocksieben); Department of Physical Medicine & Rehabilitation, Spaulding Rehabilitation Hospital, Boston, Massachusetts (O'Neil-Pirozzi); Department of Communication Sciences & Disorders, Northeastern University, Boston, Massachusetts (Dr O'Neil-Pirozzi); H. Ben Taub Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston, Texas (Dr Sander); Brain Injury Research Center, TIRR Memorial Hermann, Houston, Texas (Dr Sander); Department of Research, Craig Hospital, Englewood, Colorado (Drs Agtarap and Finn); Departments of Ophthalmology & Visual Sciences and Physical Medicine & Rehabilitation, University of Alabama at Birmingham, Birmingham, Alabama (Dr Dreer); Research Service, James A. Haley Veterans Hospital, Tampa, Florida (Dr Cotner); Research Service, Traumatic Brain Injury Center of Excellence at James A. Haley Veterans Hospital, Tampa, Florida (Drs Cotner and Nakase-Richardson); Research Department, Central Virginia Veterans Affairs Health Care System, Richmond, Virginia (Mss Vargas, and Dini, and Dr Perrin); Department of Psychology, Virginia Commonwealth University, Richmond, Virginia (Ms Vargas); Department of Psychology, University of Virginia, Charlottesville, Virginia (Ms Dini and Dr Perrin); Mental Health, School of Data Science, University of Virginia, Charlottesville, Virginia (Dr Perrin); Mental Health and Behavioral Services, James A. Haley Veterans Hospital, Tampa, Florida (Drs Finn and Nakase-Richardson); and Department of Internal Medicine, Pulmonary and Sleep Medicine Division, University of South Florida, Tampa, Florida (Dr Nakase-Richardson).
Objective: To describe the self-reported needs of family caregivers of service members and veterans (SMVs) with traumatic brain injury (TBI) at 10 to 15 years post-injury and to identify unique predictors of unmet family needs.
Setting: Five Department of Veterans Affairs Polytrauma Rehabilitation Centers.
Participants: A total of 209 family caregivers of SMVs with TBI from the VA TBI Model Systems national database who completed a 10- or 15-year follow-up assessment.
Oral Maxillofac Surg
January 2025
North Cumbria University Hospitals NHS Trust, Carlisle, UK.
Introduction: Increasing emphasis has been placed on measurement of quality of life (QOL) as a central criterion for assessment of success of any medical treatment. The aim of our study was to assess the nutritional and quality of life of patient-reported outcomes among patients who have undergone laser resection of tongue cancer.
Materials And Methods: A cross-sectional study was undertaken of patients treated with KTP laser resection of T1/T2 tongue squamous cell carcinoma (SCC) between 2011-2019.
Res Dev Disabil
January 2025
Laboratory of Observation, Diagnosis, and Education, Department of Psychology and Cognitive Science - University of Trento, Via Matteo del Ben, 5B, Rovereto, TN 38068, Italy. Electronic address:
Background: Computational approaches hold significant promise for enhancing diagnosis and therapy in child and adolescent clinical practice. Clinical procedures heavily depend n vocal exchanges and interpersonal dynamics conveyed through speech. Research highlights the importance of investigating acoustic features and dyadic interactions during child development.
View Article and Find Full Text PDFJ Immunother Cancer
January 2025
Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
Purpose: BMS-986299 is a first-in-class, NOD-, LRR-, and pyrin-domain containing-3 (NLRP3) inflammasome agonist enhancing adaptive immune and T-cell memory responses.
Materials And Methods: This was a phase-I (NCT03444753) study that assessed the safety and tolerability of intra-tumoral BMS-986299 monotherapy (part 1A) and in combination (part 1B) with nivolumab, and ipilimumab in advanced solid tumors. Reported here are single-center results.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!